Lung damage in SARS‐CoV‐2 patients: Correspondence DOI
Hinpetch Daungsupawong, Viroj Wiwanitkit

European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

We would like to comment on the publication 'Lung damage in SARS-CoV-2 patients: An autopsy study era of vaccination.1' This work sheds important light how affects lung and immunization can lower death injury rates. Nonetheless, there are a few concerns that need more research. Initially, categorization SARS-CoV-2-associated causes mortality is somewhat subjective, depending whether infection categorized as main, contributing, or comorbid. To differentiate between viral contribution other infectious complicating disorders,2 it be helpful if authors provided greater clarity criteria used for these categories took into account uniform method. recommend classification accompanied by detailed determining severity COVID-19's contribution. Outling specific clinical histological indicators influence 'caused COVID-19', 'COVID-19 related' 'associated with minor COVID-19' enhance assessment. could include examples comorbidities their potential impact function influences classification. Such precision not only aid future studies but also improve understanding COVID-19 role mortality. clarification findings' dependability assessments' repeatability subsequent research (Table 1). In addition, over underlying contributing elements this trend raised brief drop incidence leading cause mortality.3 Is exclusively result higher vaccination rates, modifications treatment regimens, illness, population immunity significant factors? By addressing variables, we gain deeper comprehension dynamics influencing rates across time. Public health tactics comparable situations improved identifying characteristics may related outcomes through demographic surveys population, which age, socioeconomic status pre-existing diseases. Future use longitudinal strategy provide new insights topic. should look at long-term effects such chronic diseases recurrent respiratory symptoms addition acute damage. our view, several biomarkers valuable assessing vaccine effectiveness studies. For instance, inflammatory cytokines (such IL-6 TNF-alpha), markers (like surfactant protein A D), immune responses (including neutralizing antibodies T-cell responses) recovery following vaccination.4 recent found LDS sensitive biomarker patients severe COVID-10, while d-dimer sole predicts 1-year mortality.5 In-hospital among mild high, particularly older individuals, linked platelet count ferritin levels.6 Early identification patient management. propose prospective design enrolling confirmed tracks them time, various stages post-vaccination. control group vaccinated individuals compare outcomes. correlating levels findings, elucidate mechanisms pathology overall exams might fully capture extent recovery, take contemporary imaging methods obtain comprehensive pathology. picture disease consequences will obtained incorporating wider variety markers. The generalizability findings significantly enhanced directions broadening study's scope range demographics contexts. comparing same high-risk populations rural urban environments shed vaccines virus. Furthermore, meta-analysis incorporates conducted globally offer strong evidence guide current programs, ultimately assisting development public regulations effectively address issues associated COVID-19. make easier create focused interventions susceptible, guaranteeing advantages reach those who most. Hinpetch Daungsupawong 50% ideas, writing, analysing, approval. Viroj Wiwanitkit supervision, There no funding. have conflict interest declare. author language editing computational tool preparation article. data generated.

Language: Английский

Combined immunization with SARS-CoV-2 spike and SARS-CoV nucleocapsid protects K18-hACE2 mice but increases lung pathology DOI Creative Commons
Jae‐Kwan Kim, A. V. Kachko, Prabhuanand Selvaraj

et al.

npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 13, 2025

Abstract Vaccines against SARS-CoV-2 have targeted the spike protein and been successful at preventing disease. However, with emergence of variants, spike-specific vaccines become less effective. The nucleocapsid is relatively conserved among variants a candidate for addition to in next generation induction T cell protection. Previous studies on SARS-CoV suggested that an immune response could result enhanced Using K18-hACE2 mouse model we investigated immunization variant nucleocapsid, from SARS CoV (N1) alone or combination compared this (N2). spike-nucleocapsid-based conferred protection lungs brain decreased lung pathology control mice. higher B responses were observed N1-immunized mice prior challenge, whether delivered spike, N1 resulted increased N2. These findings suggest are safe effective, even sequences, but viral may be associated pathology, alone, due immunogenic qualities antigen.

Language: Английский

Citations

0
Lung damage in SARS‐CoV‐2 patients: Correspondence DOI
Hinpetch Daungsupawong, Viroj Wiwanitkit

European Journal of Clinical Investigation, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

We would like to comment on the publication 'Lung damage in SARS-CoV-2 patients: An autopsy study era of vaccination.1' This work sheds important light how affects lung and immunization can lower death injury rates. Nonetheless, there are a few concerns that need more research. Initially, categorization SARS-CoV-2-associated causes mortality is somewhat subjective, depending whether infection categorized as main, contributing, or comorbid. To differentiate between viral contribution other infectious complicating disorders,2 it be helpful if authors provided greater clarity criteria used for these categories took into account uniform method. recommend classification accompanied by detailed determining severity COVID-19's contribution. Outling specific clinical histological indicators influence 'caused COVID-19', 'COVID-19 related' 'associated with minor COVID-19' enhance assessment. could include examples comorbidities their potential impact function influences classification. Such precision not only aid future studies but also improve understanding COVID-19 role mortality. clarification findings' dependability assessments' repeatability subsequent research (Table 1). In addition, over underlying contributing elements this trend raised brief drop incidence leading cause mortality.3 Is exclusively result higher vaccination rates, modifications treatment regimens, illness, population immunity significant factors? By addressing variables, we gain deeper comprehension dynamics influencing rates across time. Public health tactics comparable situations improved identifying characteristics may related outcomes through demographic surveys population, which age, socioeconomic status pre-existing diseases. Future use longitudinal strategy provide new insights topic. should look at long-term effects such chronic diseases recurrent respiratory symptoms addition acute damage. our view, several biomarkers valuable assessing vaccine effectiveness studies. For instance, inflammatory cytokines (such IL-6 TNF-alpha), markers (like surfactant protein A D), immune responses (including neutralizing antibodies T-cell responses) recovery following vaccination.4 recent found LDS sensitive biomarker patients severe COVID-10, while d-dimer sole predicts 1-year mortality.5 In-hospital among mild high, particularly older individuals, linked platelet count ferritin levels.6 Early identification patient management. propose prospective design enrolling confirmed tracks them time, various stages post-vaccination. control group vaccinated individuals compare outcomes. correlating levels findings, elucidate mechanisms pathology overall exams might fully capture extent recovery, take contemporary imaging methods obtain comprehensive pathology. picture disease consequences will obtained incorporating wider variety markers. The generalizability findings significantly enhanced directions broadening study's scope range demographics contexts. comparing same high-risk populations rural urban environments shed vaccines virus. Furthermore, meta-analysis incorporates conducted globally offer strong evidence guide current programs, ultimately assisting development public regulations effectively address issues associated COVID-19. make easier create focused interventions susceptible, guaranteeing advantages reach those who most. Hinpetch Daungsupawong 50% ideas, writing, analysing, approval. Viroj Wiwanitkit supervision, There no funding. have conflict interest declare. author language editing computational tool preparation article. data generated.

Language: Английский

Citations

0